COST-EFFECTIVENESS OF EARLY VERSUS DELAYED AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MULTIPLE MYELOMA (MM)

被引：0
|
作者：
Kelkar, Amar [1 ,2 ]
Midha, Shonali [1 ,2 ]
Richardson, Paul [1 ,2 ]
Anderson, Kenneth [1 ,2 ]
Munshi, Nikhil [1 ,2 ]
Laubach, Jacob [1 ,2 ]
Ghobrial, Irene [1 ,2 ]
Mo, Clifton [1 ,2 ]
Nadeem, Omar [1 ,2 ]
Cliff, Edward [1 ,2 ]
Abel, Gregory [1 ,2 ]
Soiffer, Robert [1 ,2 ]
Cutler, Corey [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O120
引用
收藏
页码：107 / 108
页数：2
相关论文
共 50 条
  • [41] Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma
    Dunavin, Neil
    Habib, Joyce
    Phillips, Gary
    Elder, Patrick
    Tranovich, Meaghan
    Benson, Don M., Jr.
    Hofmeister, Craig C.
    Byrd, John C.
    Devine, Steven M.
    Efebera, Yvonne
    BLOOD, 2010, 116 (21) : 1466 - 1467
  • [42] Topotecan (T) and melphalan (M) with autologous stem cell transplantation (ASCT) is a safe, tolerable and effective regimen for patients with multiple myeloma (MM).
    Holman, P
    Joyce, R
    Medina, B
    Corringham, S
    Kormanik, P
    Bashey, A
    Carrier, E
    Lane, T
    O'Quigley, J
    Ball, E
    BLOOD, 2003, 102 (11) : 438B - 439B
  • [43] COST-EFFECTIVENESS ANALYSIS OF STRATEGIES OF AUTOLOGOUS STEM-CELL TRANSPLANTATION AND MAINTENANCE THERAPY FOR TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA IN CHINA
    Wu, W.
    Lou, Y.
    Fan, X.
    Ding, S.
    Zhou, Y.
    Keramat, S. A.
    Yang, W.
    Tang, F.
    Comans, T.
    Dong, H.
    VALUE IN HEALTH, 2023, 26 (12) : S195 - S195
  • [44] Autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients <60 vs ≥60 years (yrs) of age.
    Reece, DE
    Perez, WS
    Bredeson, CN
    Vesole, DH
    Horowitz, MM
    BLOOD, 2001, 98 (11) : 684A - 684A
  • [45] Autologous stem cell transplantation in multiple myeloma
    Louw, V.
    Webb, M. J.
    SOUTHERN AFRICAN JOURNAL OF ANAESTHESIA AND ANALGESIA, 2010, 16 (01) : 57 - 57
  • [46] Autologous stem cell transplantation in multiple myeloma
    Ricciuti, Giuseppina
    Falcone, Antonietta
    Cascavilla, Nicola
    Martinelli, Giovanni
    Cerchione, Claudio
    PANMINERVA MEDICA, 2020, 62 (04) : 220 - 224
  • [47] Peripheral Immune Profile and Minimal Residual Disease (MRD) Burden Following Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)
    Foureau, David
    Zhang, Qing
    Cogdill, Tammy D.
    Wynn, Adina S.
    Steuerwald, Nury M.
    Druhan, Lawrence J.
    Guo, Fei
    Rigby, Katherine
    Madden, Kyle L.
    Symanowski, James T.
    Avalos, Belinda R.
    Copelan, Edward A.
    Usmani, Saad Z.
    Bhutani, Manisha
    BLOOD, 2016, 128 (22)
  • [48] High dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in multiple myeloma (MM): An analysis of prognostic factors.
    Lalit, K
    Ganessan, K
    Wadhwa, J
    Sharma, A
    Kochupillai, V
    BLOOD, 2002, 100 (11) : 474B - 474B
  • [49] Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT
    Grovdal, M.
    Nahi, H.
    Gahrton, G.
    Liwing, J.
    Waage, A.
    Abildgaard, N.
    Pedersen, P. T.
    Hammerstrom, J.
    Laaksonen, A.
    Bazia, P.
    Terava, V.
    Ollikainen, H.
    Silvennoinen, R.
    Putkonen, M.
    Anttila, P.
    Porkka, K.
    Remes, K.
    BONE MARROW TRANSPLANTATION, 2015, 50 (06) : 808 - 812
  • [50] Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT
    M Grövdal
    H Nahi
    G Gahrton
    J Liwing
    A Waage
    N Abildgaard
    P T Pedersen
    J Hammerstrøm
    A Laaksonen
    P Bazia
    V Terava
    H Ollikainen
    R Silvennoinen
    M Putkonen
    P Anttila
    K Porkka
    K Remes
    Bone Marrow Transplantation, 2015, 50 : 808 - 812
12345